Argatroban for elective percutaneous coronary intervention: the ARG-E04 multi-center study

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Argatroban, a direct thrombin inhibitor, is approved for percutaneous coronary intervention (PCI) in patients with heparin-induced thrombocytopenia (HIT).
• Limited data exist on argatroban's use in non-HIT patients undergoing elective PCI.

Purpose of the Study:

• To evaluate the safety and efficacy of argatroban in patients undergoing elective PCI.
• To compare argatroban's anticoagulant effect with unfractionated heparin (UFH).

Main Methods:

• An open-label, multiple-dose, controlled study involving 140 patients undergoing elective PCI.
• Patients were randomized into three argatroban dose groups or one unfractionated heparin (UFH) group.
• Activated clotting time (ACT) and time to PCI initiation were primary endpoints.

Main Results:

• Argatroban dose-dependently prolonged activated clotting time (ACT), with higher target ACT achievement compared to UFH (p<0.001).
• PCI initiation time was significantly shorter in argatroban groups.
• Composite incidences of death, myocardial infarction, or urgent revascularization were similar across groups. Major bleeding occurred only with UFH.

Conclusions:

• Argatroban demonstrates a dose-dependent increase in coagulation parameters.
• Compared to UFH, argatroban provides a superior and predictable anticoagulant effect for elective PCI.
• Argatroban shows a favorable safety profile in non-HIT patients undergoing elective PCI.